{"id":10522,"date":"2025-04-09T12:02:20","date_gmt":"2025-04-09T12:02:20","guid":{"rendered":"https:\/\/navarrahealthcluster.com\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/"},"modified":"2025-04-09T13:23:39","modified_gmt":"2025-04-09T13:23:39","slug":"mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple","status":"publish","type":"post","link":"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/","title":{"rendered":"MIMO Biosciences: One year driving preclinical research against multiple myeloma"},"content":{"rendered":"\n<p><a href=\"https:\/\/navarrahealthcluster.com\/en\/partners\/mimobiosciences\/\">MIMO Biosciences<\/a>, member of Navarra Health Cluster, celebrated its first year of activity in February \u2014 a journey already marked by key milestones, including its first capital increase at the end of 2024. <\/p>\n\n\n\n<p><strong>Ricardo P\u00e9rez<\/strong>, CEO of <a href=\"https:\/\/mimobiosciences.com\/\">MIMO Biosciences<\/a>, introduces the company\u2019s work focused on preclinical-stage drug research for various types of haematological cancers, such as multiple myeloma \u2014 the second most common blood cancer and, in most cases, still incurable.<\/p>\n\n\n\n<p><em>Can you tell us how the journey of MIMO Biosciences began?<\/em><\/p>\n\n\n\n<p>MIMO Biosciences is a spin-off from <a href=\"https:\/\/navarrahealthcluster.com\/en\/partners\/cima-universidad-de-navarra\/\">Cima Universidad de Navarra<\/a> that began operations on 1 February 2024, with my appointment as CEO and the incorporation of six researchers from the <a href=\"https:\/\/cima.cun.es\/investigacion\/programas-investigacion\/programa-investigacion-hemato-oncologia\/grupo-investigacion-linfomas\">laboratory led by Jos\u00e9 \u00c1ngel Mart\u00ednez Climent<\/a>. This haematology-oncology lab at Cima focuses on the study of blood-related cancers. The team developed and refined mouse models for haematological diseases, particularly multiple myeloma and lymphoma.<br>These mice naturally develop the disease without any alteration or injection of tumour cells into their immune system \u2014 a common method in other models. Instead, they are born with a specific genetic lesion that predisposes them to develop the disease naturally within 6\u20137 months. This is exceptional in science, as these models provide more robust and reliable data than other available alternatives. The models were featured in <em>Nature Medicine<\/em> in 2023, and this publication was the catalyst for creating the company. Cima licensed the know-how and granted MIMO exclusive worldwide rights to these mouse models.      <\/p>\n\n\n\n<p><em>What does MIMO do, and what sets it apart from others?<\/em><\/p>\n\n\n\n<p>Our business model is based on testing drugs in the preclinical stage for pharmaceutical companies using these unique mouse models. We sell the information derived from these studies through a <em>fee-for-service<\/em> model. We operate on a contractual basis: we define the project scope \u2014 including the types and number of models to be used, duration, drug dosage, and other specific details \u2014 and, at the end of the process, we deliver valuable insights to help pharmaceutical companies make decisions. The type of company that provides this service is known as a CRO (Contract Research Organisation).   <\/p>\n\n\n\n<p>MIMO has three key competitive advantages:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>We own our models;<\/li>\n\n\n\n<li>We are science-based and highly flexible when executing trials \u2014 unlike a standard CRO;<\/li>\n\n\n\n<li>We are embedded in a powerful ecosystem, with access to 400 researchers at Cima and clinicians from the <a href=\"https:\/\/navarrahealthcluster.com\/en\/partners\/clinica-universidad-de-navarra\/\">Cl\u00ednica Universidad de Navarra<\/a>.<\/li>\n<\/ul>\n\n\n\n<p><em>How is the company positioned within the Navarre health ecosystem? <\/em><\/p>\n\n\n\n<p>I greatly value the support of Navarra Health Cluster. Although we haven\u2019t yet had many opportunities to collaborate, I strongly believe we\u2019ll benefit significantly from being part of this group. While 100% of our clients are based in the United States, you never know \u2014 networking activities are highly valuable, offering the chance to share experiences and tackle common challenges. The stakeholders in Navarre are world-class, and our region has the right conditions to aspire to high-impact technological projects.<\/p>\n\n\n\n<p><em>What are MIMO\u2019s prospects for 2025?<\/em><\/p>\n\n\n\n<p>One of the key milestones is our growth. In January, we welcomed a new Chief Financial Officer. This February, four new team members are joining us, and we expect to add up to seven more by the end of the year. Although we don\u2019t plan to open facilities in the United States, we are considering setting up a commercial office. <\/p>\n\n\n\n<p>Additionally, in May, we will move into new facilities on the <a href=\"https:\/\/navarrahealthcluster.com\/socias\/universidad-de-navarra\/\">University of Navarra<\/a>\u2019s campus, in the science area, within the animal research zone. It will feature a brand-new animal facility of nearly 400 square metres.<\/p>\n\n\n\n<p>Our main challenges in 2025 include consolidating our business model to become a global leader in haematological cancers. We are already leaders in multiple myeloma, and now we aim to expand into other types of myeloma and, especially, lymphoma. Finally, we intend to develop our own models with our strategic partner under \u201cfreedom to operate\u201d conditions. This was one of the main reasons for our recent capital increase. Although the competition is fierce at a global level, we are highly competitive thanks to the high quality of our services and science-driven approach.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MIMO Biosciences, member of Navarra Health Cluster, celebrated its first year of activity in February \u2014 a journey already marked by key milestones, including its first capital increase at the end of 2024. Ricardo P\u00e9rez, CEO of MIMO Biosciences, introduces the company\u2019s work focused on preclinical-stage drug research for various types of haematological cancers, such [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":10520,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[57,23],"tags":[],"class_list":["post-10522","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-sin-categorizar-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MIMO Biosciences: One year driving preclinical research against multiple myeloma<\/title>\n<meta name=\"description\" content=\"Interview with Ricardo P\u00e9rez, CEO of MIMO Biosciences, a company focused on research into drugs for various types of hematological cancers, such as multiple myeloma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MIMO Biosciences: One year driving preclinical research against multiple myeloma\" \/>\n<meta property=\"og:description\" content=\"Interview with Ricardo P\u00e9rez, CEO of MIMO Biosciences, a company focused on research into drugs for various types of hematological cancers, such as multiple myeloma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/\" \/>\n<meta property=\"og:site_name\" content=\"Navarra Health Cluster\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-09T12:02:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-09T13:23:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/navarrahealthcluster.com\/wp-content\/uploads\/Diseno-sin-titulo-30.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1300\" \/>\n\t<meta property=\"og:image:height\" content=\"867\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jessica swiderski\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jessica swiderski\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/\"},\"author\":{\"name\":\"Jessica swiderski\",\"@id\":\"https:\/\/navarrahealthcluster.com\/#\/schema\/person\/b61800fe352bcd46894619c084a53d05\"},\"headline\":\"MIMO Biosciences: One year driving preclinical research against multiple myeloma\",\"datePublished\":\"2025-04-09T12:02:20+00:00\",\"dateModified\":\"2025-04-09T13:23:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/\"},\"wordCount\":679,\"publisher\":{\"@id\":\"https:\/\/navarrahealthcluster.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/navarrahealthcluster.com\/wp-content\/uploads\/Diseno-sin-titulo-30.png\",\"articleSection\":[\"News\",\"Sin categorizar\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/\",\"url\":\"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/\",\"name\":\"MIMO Biosciences: One year driving preclinical research against multiple myeloma\",\"isPartOf\":{\"@id\":\"https:\/\/navarrahealthcluster.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/navarrahealthcluster.com\/wp-content\/uploads\/Diseno-sin-titulo-30.png\",\"datePublished\":\"2025-04-09T12:02:20+00:00\",\"dateModified\":\"2025-04-09T13:23:39+00:00\",\"description\":\"Interview with Ricardo P\u00e9rez, CEO of MIMO Biosciences, a company focused on research into drugs for various types of hematological cancers, such as multiple myeloma.\",\"breadcrumb\":{\"@id\":\"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/#primaryimage\",\"url\":\"https:\/\/navarrahealthcluster.com\/wp-content\/uploads\/Diseno-sin-titulo-30.png\",\"contentUrl\":\"https:\/\/navarrahealthcluster.com\/wp-content\/uploads\/Diseno-sin-titulo-30.png\",\"width\":1300,\"height\":867,\"caption\":\"MIMO Biosciences equipo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\/\/navarrahealthcluster.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/navarrahealthcluster.com\/en\/category\/news\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"MIMO Biosciences: One year driving preclinical research against multiple myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/navarrahealthcluster.com\/#website\",\"url\":\"https:\/\/navarrahealthcluster.com\/\",\"name\":\"Navarra Health Cluster\",\"description\":\"La mayor alianza en salud y biociencias de Navarra\",\"publisher\":{\"@id\":\"https:\/\/navarrahealthcluster.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/navarrahealthcluster.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/navarrahealthcluster.com\/#organization\",\"name\":\"Navarra Health Cluster\",\"url\":\"https:\/\/navarrahealthcluster.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/navarrahealthcluster.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/navarrahealthcluster.com\/wp-content\/uploads\/logo.png\",\"contentUrl\":\"https:\/\/navarrahealthcluster.com\/wp-content\/uploads\/logo.png\",\"width\":393,\"height\":116,\"caption\":\"Navarra Health Cluster\"},\"image\":{\"@id\":\"https:\/\/navarrahealthcluster.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/navarrahealthcluster\/posts\/?feedView=all\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/navarrahealthcluster.com\/#\/schema\/person\/b61800fe352bcd46894619c084a53d05\",\"name\":\"Jessica swiderski\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/navarrahealthcluster.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f6e6b4597cd0a87a101fb2ece2ea1ccc60a5271e09b541f3276d8e82e311a9e4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f6e6b4597cd0a87a101fb2ece2ea1ccc60a5271e09b541f3276d8e82e311a9e4?s=96&d=mm&r=g\",\"caption\":\"Jessica swiderski\"},\"url\":\"https:\/\/navarrahealthcluster.com\/en\/author\/navarra-capital\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MIMO Biosciences: One year driving preclinical research against multiple myeloma","description":"Interview with Ricardo P\u00e9rez, CEO of MIMO Biosciences, a company focused on research into drugs for various types of hematological cancers, such as multiple myeloma.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/","og_locale":"en_US","og_type":"article","og_title":"MIMO Biosciences: One year driving preclinical research against multiple myeloma","og_description":"Interview with Ricardo P\u00e9rez, CEO of MIMO Biosciences, a company focused on research into drugs for various types of hematological cancers, such as multiple myeloma.","og_url":"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/","og_site_name":"Navarra Health Cluster","article_published_time":"2025-04-09T12:02:20+00:00","article_modified_time":"2025-04-09T13:23:39+00:00","og_image":[{"width":1300,"height":867,"url":"https:\/\/navarrahealthcluster.com\/wp-content\/uploads\/Diseno-sin-titulo-30.png","type":"image\/png"}],"author":"Jessica swiderski","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Jessica swiderski","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/#article","isPartOf":{"@id":"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/"},"author":{"name":"Jessica swiderski","@id":"https:\/\/navarrahealthcluster.com\/#\/schema\/person\/b61800fe352bcd46894619c084a53d05"},"headline":"MIMO Biosciences: One year driving preclinical research against multiple myeloma","datePublished":"2025-04-09T12:02:20+00:00","dateModified":"2025-04-09T13:23:39+00:00","mainEntityOfPage":{"@id":"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/"},"wordCount":679,"publisher":{"@id":"https:\/\/navarrahealthcluster.com\/#organization"},"image":{"@id":"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/#primaryimage"},"thumbnailUrl":"https:\/\/navarrahealthcluster.com\/wp-content\/uploads\/Diseno-sin-titulo-30.png","articleSection":["News","Sin categorizar"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/","url":"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/","name":"MIMO Biosciences: One year driving preclinical research against multiple myeloma","isPartOf":{"@id":"https:\/\/navarrahealthcluster.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/#primaryimage"},"image":{"@id":"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/#primaryimage"},"thumbnailUrl":"https:\/\/navarrahealthcluster.com\/wp-content\/uploads\/Diseno-sin-titulo-30.png","datePublished":"2025-04-09T12:02:20+00:00","dateModified":"2025-04-09T13:23:39+00:00","description":"Interview with Ricardo P\u00e9rez, CEO of MIMO Biosciences, a company focused on research into drugs for various types of hematological cancers, such as multiple myeloma.","breadcrumb":{"@id":"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/#primaryimage","url":"https:\/\/navarrahealthcluster.com\/wp-content\/uploads\/Diseno-sin-titulo-30.png","contentUrl":"https:\/\/navarrahealthcluster.com\/wp-content\/uploads\/Diseno-sin-titulo-30.png","width":1300,"height":867,"caption":"MIMO Biosciences equipo"},{"@type":"BreadcrumbList","@id":"https:\/\/navarrahealthcluster.com\/en\/mimo-biosciences-un-ano-impulsando-la-investigacion-preclinica-contra-el-mieloma-multiple\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/navarrahealthcluster.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/navarrahealthcluster.com\/en\/category\/news\/"},{"@type":"ListItem","position":3,"name":"MIMO Biosciences: One year driving preclinical research against multiple myeloma"}]},{"@type":"WebSite","@id":"https:\/\/navarrahealthcluster.com\/#website","url":"https:\/\/navarrahealthcluster.com\/","name":"Navarra Health Cluster","description":"La mayor alianza en salud y biociencias de Navarra","publisher":{"@id":"https:\/\/navarrahealthcluster.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/navarrahealthcluster.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/navarrahealthcluster.com\/#organization","name":"Navarra Health Cluster","url":"https:\/\/navarrahealthcluster.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/navarrahealthcluster.com\/#\/schema\/logo\/image\/","url":"https:\/\/navarrahealthcluster.com\/wp-content\/uploads\/logo.png","contentUrl":"https:\/\/navarrahealthcluster.com\/wp-content\/uploads\/logo.png","width":393,"height":116,"caption":"Navarra Health Cluster"},"image":{"@id":"https:\/\/navarrahealthcluster.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/navarrahealthcluster\/posts\/?feedView=all"]},{"@type":"Person","@id":"https:\/\/navarrahealthcluster.com\/#\/schema\/person\/b61800fe352bcd46894619c084a53d05","name":"Jessica swiderski","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/navarrahealthcluster.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f6e6b4597cd0a87a101fb2ece2ea1ccc60a5271e09b541f3276d8e82e311a9e4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f6e6b4597cd0a87a101fb2ece2ea1ccc60a5271e09b541f3276d8e82e311a9e4?s=96&d=mm&r=g","caption":"Jessica swiderski"},"url":"https:\/\/navarrahealthcluster.com\/en\/author\/navarra-capital\/"}]}},"_links":{"self":[{"href":"https:\/\/navarrahealthcluster.com\/en\/wp-json\/wp\/v2\/posts\/10522","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/navarrahealthcluster.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/navarrahealthcluster.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/navarrahealthcluster.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/navarrahealthcluster.com\/en\/wp-json\/wp\/v2\/comments?post=10522"}],"version-history":[{"count":4,"href":"https:\/\/navarrahealthcluster.com\/en\/wp-json\/wp\/v2\/posts\/10522\/revisions"}],"predecessor-version":[{"id":10526,"href":"https:\/\/navarrahealthcluster.com\/en\/wp-json\/wp\/v2\/posts\/10522\/revisions\/10526"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/navarrahealthcluster.com\/en\/wp-json\/wp\/v2\/media\/10520"}],"wp:attachment":[{"href":"https:\/\/navarrahealthcluster.com\/en\/wp-json\/wp\/v2\/media?parent=10522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/navarrahealthcluster.com\/en\/wp-json\/wp\/v2\/categories?post=10522"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/navarrahealthcluster.com\/en\/wp-json\/wp\/v2\/tags?post=10522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}